The document provides an overview of medical device regulations in ASEAN countries. It discusses the ASEAN Medical Device Directive (AMDD), which provides harmonized regulations across ASEAN nations. It outlines the medical device classification system and regulatory registration procedure, including requirements for quality systems and clinical evaluation/investigation. Key aspects covered are the ASEAN Common Submission Dossier Template for product registration and ISO 13485 standards for quality management systems.
The document summarizes regulatory considerations for pharmaceuticals in Japan, including manufacturing, packaging, labeling, and post-marketing surveillance. For manufacturing, drugs must be approved by the Ministry of Health, Labor and Welfare and manufacturers must be licensed and follow good manufacturing practices. Packaging and labeling must contain specified information and any changes require relabeling. Post-marketing surveillance involves adverse event reporting, drug reexaminations every few years to reconfirm safety and efficacy, and reevaluations based on current medical knowledge.
The document provides guidance on the Plasma Master File (PMF) certification process and evaluation of transmissible spongiform encephalopathy (TSE) and bovine spongiform encephalopathy (BSE) risk. It outlines the PMF submission and evaluation procedure, including the use of an electronic common technical document format. It also describes TSE and BSE as rare brain diseases caused by prion proteins, and the regulatory compliance and risk assessment measures taken to prevent transmission through pharmaceutical and biological products derived from animal sources.
Regulations of Import, Sale and Manufacture of Neutraceuticals in IndiaSanthiNori1
FSSAI regulates the import, manufacture, and sale of nutraceuticals in India. It has established processes for product evaluation, analysis, and ensuring health and label claims. To import nutraceuticals, companies must follow the Foreign Trade Act and clearance occurs through 14 designated ports. Manufacture of nutraceuticals is standardized by FSSAI and ingredients must be listed in established schedules. The approval process for manufacturing involves registration of sites and licenses from FSSAI. These include basic, state, and central licenses based on annual turnover. Proper documentation is required to obtain licenses.
It contains details rules and regulations /legislation of Pharmaceuticals, Cosmetics, Active Substance Masters File, Investigational Medicinal Product Dossier for European Union
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
The document provides an overview of medical device regulations in ASEAN countries. It discusses the ASEAN Medical Device Directive (AMDD), which provides harmonized regulations across ASEAN nations. It outlines the medical device classification system and regulatory registration procedure, including requirements for quality systems and clinical evaluation/investigation. Key aspects covered are the ASEAN Common Submission Dossier Template for product registration and ISO 13485 standards for quality management systems.
The document summarizes regulatory considerations for pharmaceuticals in Japan, including manufacturing, packaging, labeling, and post-marketing surveillance. For manufacturing, drugs must be approved by the Ministry of Health, Labor and Welfare and manufacturers must be licensed and follow good manufacturing practices. Packaging and labeling must contain specified information and any changes require relabeling. Post-marketing surveillance involves adverse event reporting, drug reexaminations every few years to reconfirm safety and efficacy, and reevaluations based on current medical knowledge.
The document provides guidance on the Plasma Master File (PMF) certification process and evaluation of transmissible spongiform encephalopathy (TSE) and bovine spongiform encephalopathy (BSE) risk. It outlines the PMF submission and evaluation procedure, including the use of an electronic common technical document format. It also describes TSE and BSE as rare brain diseases caused by prion proteins, and the regulatory compliance and risk assessment measures taken to prevent transmission through pharmaceutical and biological products derived from animal sources.
Regulations of Import, Sale and Manufacture of Neutraceuticals in IndiaSanthiNori1
FSSAI regulates the import, manufacture, and sale of nutraceuticals in India. It has established processes for product evaluation, analysis, and ensuring health and label claims. To import nutraceuticals, companies must follow the Foreign Trade Act and clearance occurs through 14 designated ports. Manufacture of nutraceuticals is standardized by FSSAI and ingredients must be listed in established schedules. The approval process for manufacturing involves registration of sites and licenses from FSSAI. These include basic, state, and central licenses based on annual turnover. Proper documentation is required to obtain licenses.
It contains details rules and regulations /legislation of Pharmaceuticals, Cosmetics, Active Substance Masters File, Investigational Medicinal Product Dossier for European Union
Medical Devices registration in Japan , quality system requirements and evaluation and investigation of medical devices in regulated countries ASEAN, China JAPAN and WHO regulations. quality and ethical considerations regulatory and documentation requirements for marketing medical devices and IVDs in regulated countries.
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
1) The Global Medical Device Nomenclature (GMDN) is an internationally agreed system that provides a single common language of generic terms to uniquely identify medical devices. It aims to be adopted by medical device regulators, manufacturers and healthcare systems worldwide.
2) GMDN terms consist of a name, definition and code. Terms are searched on the GMDN agency website and used for data exchange between organizations. A unique device identifier (UDI) also uses GMDN codes.
3) GMDN was established in 1991 to allow efficient information exchange between stakeholders. It is important for regulatory approval and identification of product failures or inventory management.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
plasma master file is a EU requirement for the apploval of the biologics or the biosimilars to the EU in a eCTD format or Nees as per the requirement type and should contain the above given details
Post Marketing Requirements/Complaince: PMRs and PMCsDr. Reena Malik
This document discusses post-marketing requirements (PMRs) and post-marketing commitments (PMCs) required of drug sponsors after FDA approval. PMRs are studies required by regulation, while PMCs are studies agreed upon between the sponsor and FDA but not required. Sponsors must periodically report on the status of PMRs and PMCs, with certain details like enrollment required for clinical trials. The FDA provides guidance and websites for sponsors to report and check the status of post-marketing studies.
International Medical Device Regulators ForumSanthiNori1
The document summarizes the International Medical Device Regulators Forum (IMDRF), which was established in 2011 to accelerate international harmonization of medical device regulations. It provides background on IMDRF's establishment and membership, which includes regulators from 11 countries and regions. The document also discusses IMDRF's relationship to the prior Global Harmonization Task Force (GHTF) and describes IMDRF's management structure, meetings, and current working groups on issues like adverse event terminology and medical device cybersecurity.
The STED (Summary of Technical Documentation) is a document that manufacturers of IVD medical devices must compile to demonstrate conformity with regulations. It provides:
1) A detailed description of the device's intended purpose and performance.
2) Information on design, manufacturing, safety and performance testing to show compliance with standards.
3) A checklist mapping requirements to how the device meets each essential principle.
The STED is required for premarket review of Class C and D devices and may be requested post-market. It provides regulators a summary of a device's technical file for audit purposes. Higher risk devices require more detailed information in the STED. The level of information helps determine conformity.
1. The PMDA (Pharmaceuticals and Medical Devices Agency) is the Japanese regulatory agency that reviews submissions for drug and medical device approval to ensure safety, efficacy, and quality. It was established in 2004.
2. To market a drug in Japan, approval must be obtained for each product by demonstrating efficacy and safety through examinations. Foreign manufacturers must be accredited through the FMA process. Medical devices are classified and require pre-market notification, certification, or approval depending on the risk class.
3. Registering products in Japan requires navigating a complex process that can involve clinical trials and high fees. Pursuing product registration requires carefully considering the market demand to determine if pursuing approval is worthwhile.
Biosimilars
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). (A medicine whose active substance is made by a living organism.)
Biologicals
Biological medicines contain active substances from a biological source, such as living cells or organisms and are often produced by cutting-edge technology.
Biological medicinal product
Biological Medicinal Products, also known as biologics or biologicals, are medicinal products that are manufactured using biotechnology processes and derived from living organisms or their products. They can include vaccines, blood products, gene therapies, monoclonal antibodies, recombinant proteins, and other complex biological substances.
Biological Investigational Medicinal Product
Refer to biological products that are being investigated in clinical trials or research studies to evaluate their safety, efficacy, or pharmacokinetic properties. These products have not yet received marketing authorization and are still in the experimental phase.
In the European Union, A biological substance is referred as the active ingredient in biological products.
A "biological substance" is defined as "a substance that is produced by or extracted from a biological source
That requires a combination of physico-chemical-biological testing, along with the production process and its control, for its characterization and the determination of its quality.“
Examples: Immunologic medicines
Medicines derived from human blood and plasma
Medicines developed by means of recombinant DNA technology
Hybridoma and mAb methods
Advanced therapy medicinal products
The requirements of the EU centralized procedure.
The approval standards for biotechnology products are the same as for chemically synthesized medicines.
Both types of products must be safe and effective and have appropriate quality.
MAA for a biotechnology product must meet the standard dossier submission requirements
MAA must generally comply with the CTD format, including with respect to
Module I (administrative information, including labelling)
Module 2 (various summaries)
Module 3 (chemical, pharmaceutical, and biological information)
Module 4 (nonclinical reports)
Module 5 (clinical study reports)
The EU has approved the highest number of biosimilars worldwide, and consequently has the most extensive experience of their use and safety.
EMA has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars.
The guidelines have evolved to keep pace with rapid advances in biotechnology and analytical sciences, and they take on board increasing experience of clinical use.
All medicines produced using biotechnology and those for specific indications must be approved in the EU through EMA
Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa.
Organization structure of EMA and EDQM active Substance Master File.pptxBhavikaAPatel
The EMA is the regulatory body responsible for scientific evaluation and supervision of medicines in the EU. It has various departments that handle pre-authorization evaluation of medicines, post-authorization evaluation, veterinary medicines, communications, administration, and legal matters. The EDQM is another organization that works with the EMA to promote quality medicines in Europe through activities like developing a common pharmacopoeia and reference standards. An ASMF contains confidential intellectual property for an active substance and includes information for quality evaluation submitted to regulatory authorities through the marketing authorization process.
The document outlines good manufacturing practices (GMP) for nutraceuticals. It discusses 12 key areas that GMP for nutraceuticals covers: 1) Premises, 2) Equipment, 3) Personnel, 4) Quality Assurance, 5) Sanitation Program, 6) Operations, 7) Specifications, 8) Stability, 9) Samples, 10) Records, and 11) Recalls. Under each area, it provides details on requirements. For premises, it describes requirements for personnel and material flow, walls/ceilings, HVAC systems, utilities, and pest control. It emphasizes the need for preventative maintenance of equipment, calibration of instruments, and cleaning procedures. It also outlines personnel requirements for
GHTF group 1 is about pre market evaluation .This ppt includes brief about the group 1 , about ghtf , what it includes , study groups , definitions , classification and its rules
Clinical Research Regulation in European Union ShantanuThakre3
The document discusses clinical research regulations in the European Union. It provides information on the aim of the European Medicines Agency (EMA) in regulating clinical trials to protect subjects' rights and safety. It describes the EMA's role in ensuring good clinical practice standards across the European Economic Area. It also summarizes key points of the new Clinical Trials Regulation, including requirements for authorization, informed consent, and conducting trials on vulnerable groups. Finally, it discusses the Clinical Trials Information System that will support application and oversight of trials under the new Regulation.
The slides explain 21 CFR Part 812. It includes all the guidelines to be followed by any manufacturer and investigator while manufacturing and investigating the safety, efficacy of the medical device.
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsMichael Swit
Presentation to the Regulatory Affairs Certification (RAC) Review Course, sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group, on August 2, 2014, in Irvine, CA. See slides 4-58 for Labeling/Advertising Discussion; slide 59 to 72 for Imports/Exports, and 73 to end for Enforcement Actions
This standard provides requirements for testing dietary supplements to ensure ingredients are accurately identified and labeled. It requires supplements to be tested to confirm identity, quantity, and limits on contaminants like metals, pesticides, and microbes. The standard also provides criteria for good manufacturing practices. It applies to supplements containing vitamins, minerals, herbs, amino acids, or other botanical ingredients but excludes conventional foods.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
The document compares the clinical trial application requirements of India, the United States, and Europe. Some key differences include:
- Europe requires approval of a clinical trial application, while the US only requires an investigational new drug application be filed.
- India requires forms, documentation of chemical/toxicology data, and fees to be submitted with the application.
- The US, Europe, and India all require institutional review board or ethics committee approval before starting a trial.
- Reporting and retention of adverse events and trial records differs between the regions' regulations.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
This document summarizes a workshop on reporting medical device adverse events. It outlines who is required to report events, how to submit reports, and what happens after a report is filed. The TGA evaluates reports based on severity and likelihood, and may investigate further through testing or requesting more information from manufacturers. Potential outcomes include safety alerts, recalls, or changes to device labeling. Stricter post-market monitoring of devices was also recommended to improve adverse event analysis and information sharing between regulators.
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
This document outlines safety monitoring and adverse event reporting for medical devices from national and international perspectives. It defines medical devices and their classification system. Approval processes in India are discussed, along with the Materiovigilance Program of India for post-marketing surveillance. Adverse events must be reported within defined timeframes. International regulatory bodies like the FDA and MHRA also have mandatory reporting requirements. The limitations of current monitoring and reporting are noted.
GLOBAL MEDICAL DEVICES NOMENCLATURE.pptxSanthiNori1
1) The Global Medical Device Nomenclature (GMDN) is an internationally agreed system that provides a single common language of generic terms to uniquely identify medical devices. It aims to be adopted by medical device regulators, manufacturers and healthcare systems worldwide.
2) GMDN terms consist of a name, definition and code. Terms are searched on the GMDN agency website and used for data exchange between organizations. A unique device identifier (UDI) also uses GMDN codes.
3) GMDN was established in 1991 to allow efficient information exchange between stakeholders. It is important for regulatory approval and identification of product failures or inventory management.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
plasma master file is a EU requirement for the apploval of the biologics or the biosimilars to the EU in a eCTD format or Nees as per the requirement type and should contain the above given details
Post Marketing Requirements/Complaince: PMRs and PMCsDr. Reena Malik
This document discusses post-marketing requirements (PMRs) and post-marketing commitments (PMCs) required of drug sponsors after FDA approval. PMRs are studies required by regulation, while PMCs are studies agreed upon between the sponsor and FDA but not required. Sponsors must periodically report on the status of PMRs and PMCs, with certain details like enrollment required for clinical trials. The FDA provides guidance and websites for sponsors to report and check the status of post-marketing studies.
International Medical Device Regulators ForumSanthiNori1
The document summarizes the International Medical Device Regulators Forum (IMDRF), which was established in 2011 to accelerate international harmonization of medical device regulations. It provides background on IMDRF's establishment and membership, which includes regulators from 11 countries and regions. The document also discusses IMDRF's relationship to the prior Global Harmonization Task Force (GHTF) and describes IMDRF's management structure, meetings, and current working groups on issues like adverse event terminology and medical device cybersecurity.
The STED (Summary of Technical Documentation) is a document that manufacturers of IVD medical devices must compile to demonstrate conformity with regulations. It provides:
1) A detailed description of the device's intended purpose and performance.
2) Information on design, manufacturing, safety and performance testing to show compliance with standards.
3) A checklist mapping requirements to how the device meets each essential principle.
The STED is required for premarket review of Class C and D devices and may be requested post-market. It provides regulators a summary of a device's technical file for audit purposes. Higher risk devices require more detailed information in the STED. The level of information helps determine conformity.
1. The PMDA (Pharmaceuticals and Medical Devices Agency) is the Japanese regulatory agency that reviews submissions for drug and medical device approval to ensure safety, efficacy, and quality. It was established in 2004.
2. To market a drug in Japan, approval must be obtained for each product by demonstrating efficacy and safety through examinations. Foreign manufacturers must be accredited through the FMA process. Medical devices are classified and require pre-market notification, certification, or approval depending on the risk class.
3. Registering products in Japan requires navigating a complex process that can involve clinical trials and high fees. Pursuing product registration requires carefully considering the market demand to determine if pursuing approval is worthwhile.
Biosimilars
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). (A medicine whose active substance is made by a living organism.)
Biologicals
Biological medicines contain active substances from a biological source, such as living cells or organisms and are often produced by cutting-edge technology.
Biological medicinal product
Biological Medicinal Products, also known as biologics or biologicals, are medicinal products that are manufactured using biotechnology processes and derived from living organisms or their products. They can include vaccines, blood products, gene therapies, monoclonal antibodies, recombinant proteins, and other complex biological substances.
Biological Investigational Medicinal Product
Refer to biological products that are being investigated in clinical trials or research studies to evaluate their safety, efficacy, or pharmacokinetic properties. These products have not yet received marketing authorization and are still in the experimental phase.
In the European Union, A biological substance is referred as the active ingredient in biological products.
A "biological substance" is defined as "a substance that is produced by or extracted from a biological source
That requires a combination of physico-chemical-biological testing, along with the production process and its control, for its characterization and the determination of its quality.“
Examples: Immunologic medicines
Medicines derived from human blood and plasma
Medicines developed by means of recombinant DNA technology
Hybridoma and mAb methods
Advanced therapy medicinal products
The requirements of the EU centralized procedure.
The approval standards for biotechnology products are the same as for chemically synthesized medicines.
Both types of products must be safe and effective and have appropriate quality.
MAA for a biotechnology product must meet the standard dossier submission requirements
MAA must generally comply with the CTD format, including with respect to
Module I (administrative information, including labelling)
Module 2 (various summaries)
Module 3 (chemical, pharmaceutical, and biological information)
Module 4 (nonclinical reports)
Module 5 (clinical study reports)
The EU has approved the highest number of biosimilars worldwide, and consequently has the most extensive experience of their use and safety.
EMA has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars.
The guidelines have evolved to keep pace with rapid advances in biotechnology and analytical sciences, and they take on board increasing experience of clinical use.
All medicines produced using biotechnology and those for specific indications must be approved in the EU through EMA
Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa.
Organization structure of EMA and EDQM active Substance Master File.pptxBhavikaAPatel
The EMA is the regulatory body responsible for scientific evaluation and supervision of medicines in the EU. It has various departments that handle pre-authorization evaluation of medicines, post-authorization evaluation, veterinary medicines, communications, administration, and legal matters. The EDQM is another organization that works with the EMA to promote quality medicines in Europe through activities like developing a common pharmacopoeia and reference standards. An ASMF contains confidential intellectual property for an active substance and includes information for quality evaluation submitted to regulatory authorities through the marketing authorization process.
The document outlines good manufacturing practices (GMP) for nutraceuticals. It discusses 12 key areas that GMP for nutraceuticals covers: 1) Premises, 2) Equipment, 3) Personnel, 4) Quality Assurance, 5) Sanitation Program, 6) Operations, 7) Specifications, 8) Stability, 9) Samples, 10) Records, and 11) Recalls. Under each area, it provides details on requirements. For premises, it describes requirements for personnel and material flow, walls/ceilings, HVAC systems, utilities, and pest control. It emphasizes the need for preventative maintenance of equipment, calibration of instruments, and cleaning procedures. It also outlines personnel requirements for
GHTF group 1 is about pre market evaluation .This ppt includes brief about the group 1 , about ghtf , what it includes , study groups , definitions , classification and its rules
Clinical Research Regulation in European Union ShantanuThakre3
The document discusses clinical research regulations in the European Union. It provides information on the aim of the European Medicines Agency (EMA) in regulating clinical trials to protect subjects' rights and safety. It describes the EMA's role in ensuring good clinical practice standards across the European Economic Area. It also summarizes key points of the new Clinical Trials Regulation, including requirements for authorization, informed consent, and conducting trials on vulnerable groups. Finally, it discusses the Clinical Trials Information System that will support application and oversight of trials under the new Regulation.
The slides explain 21 CFR Part 812. It includes all the guidelines to be followed by any manufacturer and investigator while manufacturing and investigating the safety, efficacy of the medical device.
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsMichael Swit
Presentation to the Regulatory Affairs Certification (RAC) Review Course, sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group, on August 2, 2014, in Irvine, CA. See slides 4-58 for Labeling/Advertising Discussion; slide 59 to 72 for Imports/Exports, and 73 to end for Enforcement Actions
This standard provides requirements for testing dietary supplements to ensure ingredients are accurately identified and labeled. It requires supplements to be tested to confirm identity, quantity, and limits on contaminants like metals, pesticides, and microbes. The standard also provides criteria for good manufacturing practices. It applies to supplements containing vitamins, minerals, herbs, amino acids, or other botanical ingredients but excludes conventional foods.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
The document compares the clinical trial application requirements of India, the United States, and Europe. Some key differences include:
- Europe requires approval of a clinical trial application, while the US only requires an investigational new drug application be filed.
- India requires forms, documentation of chemical/toxicology data, and fees to be submitted with the application.
- The US, Europe, and India all require institutional review board or ethics committee approval before starting a trial.
- Reporting and retention of adverse events and trial records differs between the regions' regulations.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
This document summarizes a workshop on reporting medical device adverse events. It outlines who is required to report events, how to submit reports, and what happens after a report is filed. The TGA evaluates reports based on severity and likelihood, and may investigate further through testing or requesting more information from manufacturers. Potential outcomes include safety alerts, recalls, or changes to device labeling. Stricter post-market monitoring of devices was also recommended to improve adverse event analysis and information sharing between regulators.
Safety monitoring and reporting of adverse events of medical devices national...Vivek Nayak
This document outlines safety monitoring and adverse event reporting for medical devices from national and international perspectives. It defines medical devices and their classification system. Approval processes in India are discussed, along with the Materiovigilance Program of India for post-marketing surveillance. Adverse events must be reported within defined timeframes. International regulatory bodies like the FDA and MHRA also have mandatory reporting requirements. The limitations of current monitoring and reporting are noted.
The document discusses medical device adverse event reporting requirements, including definitions of reportable events and timelines for submitting reports to regulatory agencies. It provides an overview of the classification system for medical devices and regulations around reporting malfunctions, deaths and serious injuries caused by devices. Reporting requirements and challenges involving software as a medical device are also reviewed.
Presentation: Medical Devices: how to stay included workshop - Adverse event ...TGA Australia
This presentation discusses adverse event reporting including identification and reporting of adverse events, recognising avoidable errors and the difference in reporting requirements for SAS and clinical trial devices.
Devices Sponsor Information Day: 5 - Post-market - Adverse events and monitor...TGA Australia
Presentations by TGA and Industry (combined) to help sponsors and manufacturers better understand the regulation of medical devices and in-vitro diagnostic medical devices
SPONTANEOUS REPORTING SYSTEM & GUIDELINES FOR ADR REPORTING.pptxashharnomani
The document discusses spontaneous reporting systems and reporting adverse drug reactions (ADRs) to regulatory authorities. It describes the spontaneous reporting process which involves data acquisition from health professionals, data assessment of individual case reports and pooled data, and data interpretation to generate signals related to ADRs. Health professionals voluntarily report suspected ADRs directly to regulatory authorities or pharmaceutical companies. Various countries have different reporting systems, like the yellow card system in the UK. Underreporting remains a limitation of spontaneous reporting systems.
Presentation: Patient implant cards and information leaflets – implementationTGA Australia
The document discusses new requirements in Australia and Europe for providing patient implant cards and information leaflets with implantable medical devices. It outlines two models for implant cards - an EU model providing a permanent card at discharge and a US model providing a temporary card at discharge and permanent card from the manufacturer. It also discusses requirements for information to be included on patient information leaflets for implantable devices, such as device identification information, intended purpose, warnings, and adverse event reporting procedures.
The document outlines international patient safety goals and guidelines for incident reporting. It discusses 6 main safety goals, including correctly identifying patients, improving communication, and reducing healthcare-associated infections. It also defines different types of incidents like near misses, adverse events, and sentinel events. For reporting, it specifies the immediate actions required and that all incidents must be reported to the quality department within 24 hours. The purpose is to distinguish between different adverse events to improve patient safety.
Presentation: MMDR reform - Patient Implant Cards and Information LeafletsTGA Australia
The document summarizes new requirements in Australia and Europe for patient implant cards and information leaflets for implantable medical devices. Key points include:
- By 2021, implant cards and information leaflets will be required for all new and existing implantable devices in Australia, excluding simple implants like screws.
- Implant cards must include device identification and manufacturer information. Leaflets must include intended use, risks, warnings, and contact information.
- Consultations found support for the changes but also a desire from consumers and hospitals for more detailed information on risks, precautions, and reporting problems.
- Health professionals and consumers are encouraged to report any device issues to help monitor safety, but reporting rates remain low.
The regulation of medical devices in AustraliaTGA Australia
The regulation of medical devices in Australia involves classifying devices based on their intended use and risk level. Higher risk devices undergo more rigorous assessment procedures to ensure they meet essential safety and performance principles before being approved for market. Ongoing monitoring is also conducted after devices enter the market to protect public health. The TGA regulates medical devices to confirm they are suitable for their intended purpose and that their benefits outweigh any risks when used correctly.
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015KCR
How to get the plausible and precise safety data, maintaining the highest ethical standards
during clinical development?
KCR’s article presents critical points in safety monitoring and reporting at different stages of the clinical trial, as well the main difficulties faced by medical personnel and clinical team during their everyday practice.
MedWatch is the FDA's program for monitoring the safety of medical products. It allows voluntary reporting of adverse events by the public and healthcare professionals. Reports are collected in a database and monitored by FDA professionals. The FDA uses these reports to identify safety issues, communicate new safety information to the public and healthcare providers, and take regulatory actions like requiring label changes or product recalls when needed. The goal is to help protect public health by ensuring the safety of drugs, medical devices and other medical products.
IMPACT OF APPLYING INTERNATIONAL QUALITY STANDARDS ON MEDICAL EQUIPMENT IN SA...ijcax
This document summarizes a study on the impact of applying international quality standards on medical equipment in Saudi Arabia. A questionnaire was distributed to 300 healthcare professionals in public and private hospitals to collect data. The results showed that around 80% of respondents strongly agreed that international standards like ISO have significantly improved safety, testing and calibration of medical devices, use of consistent terminology, and compatibility/interoperability. Adopting global quality standards appears to have reduced risks associated with medical equipment and enhanced patient safety in Saudi Arabia according to the healthcare workers surveyed.
Postmarket monitoring of therapeutic goods in AustraliaTGA Australia
View this presentation for information on:
* what postmarket monitoring is and why it is important
* tools used in postmarket monitoring, including risk management plans
* managing risk and adverse events
* the TGA's early warning system and recall actions.
ADR reporting (Clinical Research & Pharmacovigilance).pptxDureshahwar khan
The content here, include passive surveillance system, ADR reporting, ADR reporting process, different countries ADR reporting systems, what to report?, how to report?, where to report?, Health professionals are encouraged to report adverse reactions which they believe to be drug related directly to The regulatory authority or The company marketing the suspected product on voluntary basis.
Chapter wise All Notes of First year Basic Civil Engineering.pptxDenish Jangid
Chapter wise All Notes of First year Basic Civil Engineering
Syllabus
Chapter-1
Introduction to objective, scope and outcome the subject
Chapter 2
Introduction: Scope and Specialization of Civil Engineering, Role of civil Engineer in Society, Impact of infrastructural development on economy of country.
Chapter 3
Surveying: Object Principles & Types of Surveying; Site Plans, Plans & Maps; Scales & Unit of different Measurements.
Linear Measurements: Instruments used. Linear Measurement by Tape, Ranging out Survey Lines and overcoming Obstructions; Measurements on sloping ground; Tape corrections, conventional symbols. Angular Measurements: Instruments used; Introduction to Compass Surveying, Bearings and Longitude & Latitude of a Line, Introduction to total station.
Levelling: Instrument used Object of levelling, Methods of levelling in brief, and Contour maps.
Chapter 4
Buildings: Selection of site for Buildings, Layout of Building Plan, Types of buildings, Plinth area, carpet area, floor space index, Introduction to building byelaws, concept of sun light & ventilation. Components of Buildings & their functions, Basic concept of R.C.C., Introduction to types of foundation
Chapter 5
Transportation: Introduction to Transportation Engineering; Traffic and Road Safety: Types and Characteristics of Various Modes of Transportation; Various Road Traffic Signs, Causes of Accidents and Road Safety Measures.
Chapter 6
Environmental Engineering: Environmental Pollution, Environmental Acts and Regulations, Functional Concepts of Ecology, Basics of Species, Biodiversity, Ecosystem, Hydrological Cycle; Chemical Cycles: Carbon, Nitrogen & Phosphorus; Energy Flow in Ecosystems.
Water Pollution: Water Quality standards, Introduction to Treatment & Disposal of Waste Water. Reuse and Saving of Water, Rain Water Harvesting. Solid Waste Management: Classification of Solid Waste, Collection, Transportation and Disposal of Solid. Recycling of Solid Waste: Energy Recovery, Sanitary Landfill, On-Site Sanitation. Air & Noise Pollution: Primary and Secondary air pollutants, Harmful effects of Air Pollution, Control of Air Pollution. . Noise Pollution Harmful Effects of noise pollution, control of noise pollution, Global warming & Climate Change, Ozone depletion, Greenhouse effect
Text Books:
1. Palancharmy, Basic Civil Engineering, McGraw Hill publishers.
2. Satheesh Gopi, Basic Civil Engineering, Pearson Publishers.
3. Ketki Rangwala Dalal, Essentials of Civil Engineering, Charotar Publishing House.
4. BCP, Surveying volume 1
Leveraging Generative AI to Drive Nonprofit InnovationTechSoup
In this webinar, participants learned how to utilize Generative AI to streamline operations and elevate member engagement. Amazon Web Service experts provided a customer specific use cases and dived into low/no-code tools that are quick and easy to deploy through Amazon Web Service (AWS.)
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
Beyond Degrees - Empowering the Workforce in the Context of Skills-First.pptxEduSkills OECD
Iván Bornacelly, Policy Analyst at the OECD Centre for Skills, OECD, presents at the webinar 'Tackling job market gaps with a skills-first approach' on 12 June 2024
This document provides an overview of wound healing, its functions, stages, mechanisms, factors affecting it, and complications.
A wound is a break in the integrity of the skin or tissues, which may be associated with disruption of the structure and function.
Healing is the body’s response to injury in an attempt to restore normal structure and functions.
Healing can occur in two ways: Regeneration and Repair
There are 4 phases of wound healing: hemostasis, inflammation, proliferation, and remodeling. This document also describes the mechanism of wound healing. Factors that affect healing include infection, uncontrolled diabetes, poor nutrition, age, anemia, the presence of foreign bodies, etc.
Complications of wound healing like infection, hyperpigmentation of scar, contractures, and keloid formation.
4. >
<
INTRODUCTION:
Medical Device: A medical device can be any
instrument, apparatus, implement, machine,
appliance, implant, reagent for in vitro use,
software, material or other similar or related
article, intended by the manufacturer to be used,
alone or in combination for a medical purpose.
4
6. >
<
INTRODUCTION:
Classification of MD (USFDA)
Medical Devices
Risk-Based
Classifications
Class I
Low Risk
Eg: Bandages
Class II Moderate Risk
Eg: Nebulizers
Class III High Risk
Eg: Pacemakers
6
7. >
<
INTRODUCTION:
Classification of MD (EU)
Medical Devices
Risk-Based
Classifications
Class I
Low Risk
Eg: Wheelchair
Class IIa
Moderate Risk
Eg: Hearing
Aids
Class IIb
Potential Risk
Eg: Infusion
Pumps
Class III
High Risk
Eg: Stunt grafts
7
8. >
<
Adverse Event Reporting of Medical
Device:
Adverse Event includes undesirable medical
condition that can be symptoms (nausea, chest
pain), signs (tachycardia, enlarged liver) or the
abnormal results of an investigation (laboratory
findings, electrocardiogram).
Adverse Events are not necessarily caused by the
medication – the event just needs to have occurred
after taking a medicine. 8
9. >
<
OBJECTIVES:
• Importance of monitoring patients for an adverse
event.
• Identify the common causes of an adverse event.
• Review the management of an adverse event.
• Review the outcomes for patients affected by an
adverse event.
9
10. >
<
ABOUT EVENTS:
An Event has Occurred
The manufacturer becomes aware of information
regarding an event which has occurred with its
device.
10
11. >
<
ABOUT EVENTS:
Typical events are:
a) A malfunction or deterioration in the characteristics or
performance.
b) An incorrect or out of specification test result.
c) The discovery of a design flaw during design review.
d) An inaccuracy in the labelling, instructions for use
and/or promotional materials.
11
12. >
<
ABOUT EVENTS:
The Manufacturer’s Device is Associated with
the Event.
• Complaint trends
• History of previous similar events.
• Information collected from healthcare professional
about the event.
12
13. >
<
ABOUT EVENTS:
The Event Led to One of the Following Outcomes:
• Death of a Patient, User
• Serious Injury of a Patient, User
• No death or serious injury occurred but the event
might lead to death or serious injury of a patient,
User or Other Person if the event reoccurs.
13
14. >
<
ABOUT EVENTS:
Examples of Reportable Events:
• Loss of sensing after a pacemaker has reached end of life.
• Adverse reaction of an orthopaedic implant due to
loosening.
• A batch of out-of-specification blood glucose test strips is
released. Patient uses strips according to instructions, but
readings provide incorrect values leading to incorrect
insulin dosage, resulting in hypoglycaemic shock and AE.
• Unprotected ECG cable plugged into the main electricity
supply – patient died.
14
15. >
<
WHO CAN REPORT?
• All healthcare clinicians, pharmacists, nurses &
patients, biomedical/clinical engineers, hospital
technology managers /technicians
15
16. >
<
WHOM TO REPORT?
• Adverse Events must be reported to a regulatory
Authority according to applicable requirements in
each jurisdiction.
• Regulatory Authorities should provide a contact
point to manufacturers for reporting.
16
17. >
<
TIMING FOR REPORTING:
• All other reportable events must be reported as soon
as possible by the manufacturer, but not later than
30-elapsed calendar days following the date of
awareness of the event.
• If after becoming aware of a potentially reportable
adverse event, there is still uncertainty about
whether the event is reportable, the manufacturer
must submit a report within the timeframe required
for that type of event.
17
18. >
<
TIMING FOR REPORTING:
• All report times refer to when the authority must
first be notified.
• This notification may be in the form of an initial
report, final report or trend report as required.
• If additional information is required, the
manufacturer should provide a follow-up or final
report as soon as the information is available or as
requested by the authority. 18
19. >
<
TIMEFRAME FOR REPORTING:
19
Reporter What to Report To Whom When
Manufacturers Medical device adverse event
(MDAE) or incident on
MDAE reporting form with
causality assessment report.
MvPI Within 30 calendar days
of becoming aware of an
event.
Manufacturers Reports for an event on
MDAE reporting form with
remedial action to prevent an
unreasonable risk of
substantial harm to public
health.
MvPI Within 5 work days of
becoming aware of an
event.
Healthcare service
provider
Medical device adverse event
or incident on MDAE
reporting form with causality
assessment report.
MvPI MDAE reporting form
within 5 work days of
becoming aware and root
cause analysis in next 30
calendar days.